ProQR Therapeutics NV
PRQR1.500USD
+0.040+2.74%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
161.57MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über ProQR Therapeutics NV Unternehmen
ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
ProQR Therapeutics NV Informationen
BörsenkürzelPRQR
Name des UnternehmensProQR Therapeutics NV
IPO-datumSep 18, 2014
CEOde Boer (Daniel Anton)
Anzahl der mitarbeiter166
WertpapierartOrdinary Share
GeschäftsjahresendeSep 18
AddresseZernikedreef 9
StadtLEIDEN
BörseNASDAQ OMX - NASDAQ BASIC
LandNetherlands
Postleitzahl2333 CK
Telefon31881667000
Websitehttps://www.proqr.com/
BörsenkürzelPRQR
IPO-datumSep 18, 2014
CEOde Boer (Daniel Anton)
Führungskräfte von ProQR Therapeutics NV
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
+824388.00%
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
--
Mr. Rene K. Beukema
Mr. Rene K. Beukema
Chief Corporate Development Officer, General Counsel, Executive Director
Chief Corporate Development Officer, General Counsel, Executive Director
--
--
Ms. Alison F. Lawton
Ms. Alison F. Lawton
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Bart Filius
Mr. Bart Filius
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Theresa M. Heggie
Ms. Theresa M. Heggie
Non-Executive Director
Non-Executive Director
--
--
Ms. Sarah Kiely
Ms. Sarah Kiely
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Ms. Sheila Sponselee
Ms. Sheila Sponselee
Chief People and Operations Officer
Chief People and Operations Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
+824388.00%
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
--
Mr. Rene K. Beukema
Mr. Rene K. Beukema
Chief Corporate Development Officer, General Counsel, Executive Director
Chief Corporate Development Officer, General Counsel, Executive Director
--
--
Ms. Alison F. Lawton
Ms. Alison F. Lawton
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sat, Jan 31
Aktualisiert: Sat, Jan 31
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Eli Lilly and Company
16.04%
Van Herk Investments
14.60%
Adage Capital Management, L.P.
5.94%
Privium Fund Management BV
5.09%
Affinity Asset Advisors LLC
3.42%
Andere
54.92%
Aktionäre
Aktionäre
Anteil
Eli Lilly and Company
16.04%
Van Herk Investments
14.60%
Adage Capital Management, L.P.
5.94%
Privium Fund Management BV
5.09%
Affinity Asset Advisors LLC
3.42%
Andere
54.92%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
18.45%
Corporation
16.07%
Family Office
14.60%
Investment Advisor
10.96%
Investment Advisor/Hedge Fund
5.66%
Research Firm
3.13%
Individual Investor
2.03%
Andere
29.10%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
118
40.27M
38.22%
-4.52M
2025Q3
111
41.68M
39.56%
-4.38M
2025Q2
122
61.04M
57.95%
-6.05M
2025Q1
131
62.09M
59.01%
-3.97M
2024Q4
135
61.46M
58.04%
+24.32M
2024Q3
126
39.02M
42.64%
-5.37M
2024Q2
127
38.86M
42.67%
-6.74M
2024Q1
137
38.95M
43.54%
-15.29M
2023Q4
162
39.95M
44.78%
-23.51M
2023Q3
167
40.45M
49.96%
-14.58M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Eli Lilly and Company
16.90M
16.04%
+3.52M
+26.35%
Dec 31, 2024
Van Herk Investments
14.33M
13.6%
+2.13M
+17.44%
Sep 29, 2025
Adage Capital Management, L.P.
6.25M
5.94%
-348.47K
-5.28%
Sep 30, 2025
Privium Fund Management BV
5.00M
4.74%
+725.00
+0.01%
Sep 30, 2025
Affinity Asset Advisors LLC
3.60M
3.42%
+100.49K
+2.87%
Sep 30, 2025
abrdn Inc.
2.30M
2.18%
+448.48K
+24.24%
Sep 30, 2025
Morgan Stanley & Co. LLC
2.89M
2.75%
-171.79K
-5.61%
Sep 30, 2025
Sio Capital Management, LLC
2.08M
1.97%
--
--
Sep 30, 2025
Kynam Capital Management LP
1.65M
1.57%
--
--
Sep 30, 2025
Dafna Capital Management, LLC
1.57M
1.49%
--
--
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Avantis International Small Cap Equity ETF
0.01%
Avantis International Small Cap Value ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Avantis International Small Cap Equity ETF
Anteil0.01%
Avantis International Small Cap Value ETF
Anteil0%
Invesco NASDAQ Future Gen 200 ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
